JP2022547552A5 - - Google Patents
Info
- Publication number
- JP2022547552A5 JP2022547552A5 JP2022515826A JP2022515826A JP2022547552A5 JP 2022547552 A5 JP2022547552 A5 JP 2022547552A5 JP 2022515826 A JP2022515826 A JP 2022515826A JP 2022515826 A JP2022515826 A JP 2022515826A JP 2022547552 A5 JP2022547552 A5 JP 2022547552A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962898896P | 2019-09-11 | 2019-09-11 | |
| US62/898,896 | 2019-09-11 | ||
| US202062985808P | 2020-03-05 | 2020-03-05 | |
| US62/985,808 | 2020-03-05 | ||
| PCT/US2020/050090 WO2021050656A1 (en) | 2019-09-11 | 2020-09-10 | Compositions and methods comprising prostate stem cell antigen (psca) chimeric antigen receptors (cars) |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022547552A JP2022547552A (ja) | 2022-11-14 |
| JPWO2021050656A5 JPWO2021050656A5 (https=) | 2023-09-14 |
| JP2022547552A5 true JP2022547552A5 (https=) | 2023-09-14 |
| JP7682859B2 JP7682859B2 (ja) | 2025-05-26 |
Family
ID=74849499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022515826A Active JP7682859B2 (ja) | 2019-09-11 | 2020-09-10 | 前立腺幹細胞抗原（ｐｓｃａ）キメラ抗原受容体（ｃａｒ）を含む組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11766453B2 (https=) |
| EP (1) | EP4028414A4 (https=) |
| JP (1) | JP7682859B2 (https=) |
| CN (1) | CN114729059A (https=) |
| AU (1) | AU2020347171A1 (https=) |
| WO (1) | WO2021050656A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112022023371A2 (pt) * | 2020-05-22 | 2022-12-20 | Chongqing Prec Biotech Co Ltd | Proteína de fusão para reversão do microambiente tumoral, vetor de expressão, célula imune, receptor de antígeno quimérico resistente à imunossupressão tumoral, sequência de ácido nucleico, método para preparar uma célula imune, composição farmacêutica, e, uso da composição farmacêutica |
| EP4479068A4 (en) * | 2022-02-18 | 2026-01-07 | Univ California | ENHANCED MULTIPLICATION AND FUNCTION OF PRIMARY HUMAN NK CELLS BY A CHIMERICAL CYTOKINE RECEPTOR |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| KR20250158048A (ko) | 2023-03-03 | 2025-11-05 | 아스널 바이오사이언시스, 인크. | Psma 및 ca9을 표적으로 하는 시스템 |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025235801A1 (en) | 2024-05-08 | 2025-11-13 | City Of Hope | Antibodies targeted to osteopontin and uses thereof for reducing resistance of solid tumors immune cell therapy |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ556661A (en) | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
| US8940298B2 (en) * | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
| NZ591087A (en) * | 2008-10-01 | 2012-08-31 | Micromet Ag | Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody |
| WO2013126712A1 (en) * | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| KR20150029714A (ko) * | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 ｃａｒ 세포의 활성 증강 |
| EP2906684B8 (en) * | 2012-10-10 | 2020-09-02 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| AU2014240083C1 (en) * | 2013-03-15 | 2019-10-24 | Celgene Corporation | Modified T lymphocytes |
| EP3593812A3 (en) * | 2014-03-15 | 2020-05-27 | Novartis AG | Treatment of cancer using chimeric antigen receptor |
| JP7372728B2 (ja) * | 2014-10-31 | 2023-11-01 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 改変ｔ細胞に関する方法および組成物 |
| BR112018006991A2 (en) * | 2015-10-06 | 2018-10-16 | City Of Hope | psca-targeted chimeric antigen receptors |
| WO2017212250A1 (en) | 2016-06-06 | 2017-12-14 | Polytherics Limited | Antibodies, uses thereof and conjugates thereof |
| GB201614162D0 (en) | 2016-08-18 | 2016-10-05 | Polytherics Ltd | Antibodies, uses thereof and conjugates thereof |
| CN108395480A (zh) | 2017-02-08 | 2018-08-14 | 广州百尼夫生物科技有限公司 | 嵌合抗原受体及其基因和重组表达载体、carher2-nkt细胞及其制备方法和应用 |
| TW201900672A (zh) * | 2017-03-27 | 2019-01-01 | 瑞士商赫孚孟拉羅股份公司 | 改良之抗原結合受體型式 |
| WO2018191490A1 (en) * | 2017-04-13 | 2018-10-18 | The Trustees Of The University Of Pennsylvania | Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy |
| WO2019118508A1 (en) * | 2017-12-12 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Genetically modified immune cells targeting ny-eso-1 and methods of use thereof |
| CN109593726A (zh) * | 2018-12-26 | 2019-04-09 | 重庆精准生物技术有限公司 | 增强car-t细胞归巢到实体肿瘤组织能力的试剂及其应用 |
-
2020
- 2020-09-10 WO PCT/US2020/050090 patent/WO2021050656A1/en not_active Ceased
- 2020-09-10 AU AU2020347171A patent/AU2020347171A1/en active Pending
- 2020-09-10 JP JP2022515826A patent/JP7682859B2/ja active Active
- 2020-09-10 EP EP20863540.9A patent/EP4028414A4/en active Pending
- 2020-09-10 US US17/017,238 patent/US11766453B2/en active Active
- 2020-09-10 CN CN202080078234.1A patent/CN114729059A/zh active Pending
-
2023
- 2023-09-08 US US18/463,630 patent/US20240041921A1/en active Pending